{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:30:17Z","timestamp":1792791017130,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran","award":["CMRC-0046"],"award-info":[{"award-number":["CMRC-0046"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49196-6","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:24:20Z","timestamp":1777058660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment"],"prefix":"10.1038","volume":"16","author":[{"given":"Saeedeh","family":"Shariati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokooh","family":"Mohtadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Molavinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Salehcheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farzaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"49196_CR1","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15 (2020).","journal-title":"Med. Sci."},{"key":"49196_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bju.15983","volume":"132","author":"F Mignot","year":"2023","unstructured":"Mignot, F. et al. Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. BJU Int. 132, 56\u201364 (2023).","journal-title":"BJU Int."},{"key":"49196_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LM van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L. M. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat. reviews Clin. Oncol. 20, 287\u2013304 (2023).","journal-title":"Nat. reviews Clin. Oncol."},{"key":"49196_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/10105395221136181","volume":"35","author":"AM Karam","year":"2023","unstructured":"Karam, A. M. et al. Awareness of Bladder Cancer Symptoms and Risk Factors in Jordan: A Nationwide Study. Asia Pac. J. Public. Health. 35, 69\u201372 (2023).","journal-title":"Asia Pac. J. Public. Health"},{"key":"49196_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/cancers15030668","volume":"15","author":"H Kamecki","year":"2023","unstructured":"Kamecki, H. et al. Incidental diagnosis of urothelial bladder cancer: associations with overall survival. Cancers 15, 668 (2023).","journal-title":"Cancers"},{"key":"49196_CR6","first-page":"97","volume":"11","author":"A Brown","year":"2019","unstructured":"Brown, A., Kumar, S. & Tchounwou, P. B. Cisplatin-based chemotherapy of human cancers. J. cancer Sci. therapy. 11, 97 (2019).","journal-title":"J. cancer Sci. therapy"},{"key":"49196_CR7","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li, F. et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist. Updates. 68, 100938 (2023).","journal-title":"Drug Resist. Updates"},{"key":"49196_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4103\/jcrt.jcrt_792_22","volume":"19","author":"A Bhat","year":"2023","unstructured":"Bhat, A. et al. Cisplatin-based combination therapy for cancer. J. Cancer Res. Ther. 19, 530\u2013536 (2023).","journal-title":"J. Cancer Res. Ther."},{"key":"49196_CR9","doi-asserted-by":"publisher","first-page":"17610","DOI":"10.3390\/ijms242417610","volume":"24","author":"FC Kuan","year":"2023","unstructured":"Kuan, F. C., Li, J. M., Huang, Y. C., Chang, S. F. & Shi, C. S. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial\u2013Mesenchymal Transition and Stemness Properties. Int. J. Mol. Sci. 24, 17610 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"49196_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4093\/dmj.2025.0964","volume":"50","author":"YK Cho","year":"2026","unstructured":"Cho, Y. K. & Jung, C. H. Sodium-Glucose Cotransporter 2 Inhibitors as Emerging Anticancer Agents. Diabetes Metabolism J. 50, 1 (2026).","journal-title":"Diabetes Metabolism J."},{"key":"49196_CR11","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed. Pharmacother. 132, 110821. https:\/\/doi.org\/10.1016\/j.biopha.2020.110821 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"49196_CR12","doi-asserted-by":"crossref","unstructured":"Sathe, A. & Nawroth, R. Targeting the PI3K\/AKT\/mTOR pathway in bladder cancer. Urothelial carcinoma: Methods protocols, 335\u2013350 (2017).","DOI":"10.1007\/978-1-4939-7234-0_23"},{"key":"49196_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jhbp.1391","volume":"31","author":"S Fujiyoshi","year":"2024","unstructured":"Fujiyoshi, S. et al. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma. J. Hepato-Biliary-Pancreatic Sci. 31, 223\u2013233 (2024).","journal-title":"J. Hepato-Biliary-Pancreatic Sci."},{"key":"49196_CR14","doi-asserted-by":"publisher","first-page":"175565","DOI":"10.1016\/j.ejphar.2023.175565","volume":"943","author":"LV Nalla","year":"2023","unstructured":"Nalla, L. V. & Khairnar, A. Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur. J. Pharmacol. 943, 175565 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"49196_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12672-023-00719-x","volume":"14","author":"W Wu","year":"2023","unstructured":"Wu, W., Wang, Y., Xie, J. & Fan, S. Empagliflozin: a potential anticancer drug. Discover Oncol. 14, 127 (2023).","journal-title":"Discover Oncol."},{"key":"49196_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neuro.2024.10.006","volume":"105","author":"MM Nasr","year":"2024","unstructured":"Nasr, M. M., Wahdan, S. A., El-Naga, R. N. & Salama, R. M. Neuroprotective effect of empagliflozin against doxorubicin-induced chemobrain in rats: Interplay between SIRT-1\/MuRF-1\/PARP-1\/NLRP3 signaling pathways and enhanced expression of miRNA-34a and LncRNA HOTAIR. Neurotoxicology 105, 216\u2013230 (2024).","journal-title":"Neurotoxicology"},{"key":"49196_CR17","doi-asserted-by":"publisher","first-page":"A392","DOI":"10.1210\/jendso\/bvac150.815","volume":"6","author":"A Alzenaidi","year":"2022","unstructured":"Alzenaidi, A. & Alkhalidi, H. PSUN250 Empagliflozin Induced Bladder Cancer in an Adult Patient With Latent Autoimmune Diabetes. J. Endocr. Soc. 6, A392 (2022).","journal-title":"J. Endocr. Soc."},{"key":"49196_CR18","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.amjmed.2019.08.006","volume":"132","author":"JB McGill","year":"2019","unstructured":"McGill, J. B. & Subramanian, S. Safety of sodium-glucose co-transporter 2 inhibitors. Am. J. Med. 132, S49\u2013S57 (2019).","journal-title":"Am. J. Med."},{"key":"49196_CR19","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2337\/dc22-1174","volume":"45","author":"D Abrahami","year":"2022","unstructured":"Abrahami, D. et al. Sodium\u2013glucose cotransporter 2 inhibitors and the short-term risk of bladder cancer: an international multisite cohort study. Diabetes Care. 45, 2907\u20132917 (2022).","journal-title":"Diabetes Care"},{"key":"49196_CR20","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.2337\/dc21-1917","volume":"45","author":"P Ueda","year":"2022","unstructured":"Ueda, P. et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. Diabetes Care. 45, e93\u2013e96. https:\/\/doi.org\/10.2337\/dc21-1917 (2022).","journal-title":"Diabetes Care"},{"key":"49196_CR21","doi-asserted-by":"publisher","unstructured":"Pandey, A. et al. Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities. Cancers (Basel). 17 https:\/\/doi.org\/10.3390\/cancers17030466 (2025).","DOI":"10.3390\/cancers17030466"},{"key":"49196_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/ijms22041680","volume":"22","author":"M D\u0105browski","year":"2021","unstructured":"D\u0105browski, M. & Diabetes antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors. Int. J. Mol. Sci. 22, 1680 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"49196_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000102917","volume":"79","author":"T Powles","year":"2007","unstructured":"Powles, T. et al. A comparison of the platinum analogues in bladder cancer cell lines. Urol. Int. 79, 67\u201372 (2007).","journal-title":"Urol. Int."},{"key":"49196_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00210-024-03316-z","volume":"398","author":"A Karzoon","year":"2025","unstructured":"Karzoon, A., Yerer, M. B. & Cumao\u011flu, A. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects. Naunyn. Schmiedebergs Arch. Pharmacol. 398, 781\u2013798 (2025).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"49196_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12951-023-01840-3","volume":"21","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma. J. Nanobiotechnol. 21, 89 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"49196_CR26","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1007\/s00432-023-04641-1","volume":"149","author":"KK To","year":"2023","unstructured":"To, K. K., Cheung, K. M. & Cho, W. C. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment. J. Cancer Res. Clin. Oncol. 149, 7217\u20137234 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"49196_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1039\/C4MT00238E","volume":"6","author":"ND Eljack","year":"2014","unstructured":"Eljack, N. D. et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 6, 2126\u20132133 (2014).","journal-title":"Metallomics"},{"key":"49196_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jebm.12434","volume":"14","author":"JQ Wang","year":"2021","unstructured":"Wang, J. Q. et al. ATP-binding cassette (ABC) transporters in cancer: a review of recent updates. J. Evidence-Based Med. 14, 232\u2013256 (2021).","journal-title":"J. Evidence-Based Med."},{"key":"49196_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/antiox11071324","volume":"11","author":"Y Tang","year":"2022","unstructured":"Tang, Y. et al. Metabolic adaptation-mediated cancer survival and progression in oxidative stress. Antioxidants 11, 1324 (2022).","journal-title":"Antioxidants"},{"key":"49196_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/08923973.2022.2143371","volume":"45","author":"EH Hassanein","year":"2023","unstructured":"Hassanein, E. H. et al. Neuroprotective effect of canagliflozin against cisplatin-induced cerebral cortex injury is mediated by regulation of HO-1\/PPAR-\u03b3, SIRT1\/FOXO-3, JNK\/AP-1, TLR4\/iNOS, and Ang II\/Ang 1\u20137 signals. Immunopharmacol. Immunotoxicol. 45, 304\u2013316 (2023).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"49196_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s40001-025-02749-3","volume":"30","author":"J Li","year":"2025","unstructured":"Li, J. et al. Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology\u2014a narrative review. Eur. J. Med. Res. 30, 520 (2025).","journal-title":"Eur. J. Med. Res."},{"key":"49196_CR32","doi-asserted-by":"crossref","unstructured":"Dos Santos, V. A. et al. Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. Scientific Reports (2025).","DOI":"10.1038\/s41598-025-27555-z"},{"key":"49196_CR33","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/dom.13745","volume":"21","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini, I., Nreu, B., Mannucci, E. & Monami, M. Sodium-glucose co\u2010transporter\u20102 (SGLT\u20102) inhibitors and cancer: a meta\u2010analysis of randomized controlled trials. Diabetes Obes. Metabolism. 21, 1871\u20131877 (2019).","journal-title":"Diabetes Obes. Metabolism"},{"key":"49196_CR34","doi-asserted-by":"publisher","first-page":"691795","DOI":"10.3389\/fmolb.2021.691795","volume":"8","author":"L Wang","year":"2021","unstructured":"Wang, L., Zhao, X., Fu, J., Xu, W. & Yuan, J. The role of tumour metabolism in cisplatin resistance. Front. Mol. Biosci. 8, 691795 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"49196_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/hearts5040039","volume":"5","author":"L Piras","year":"2024","unstructured":"Piras, L. et al. Double duty: SGLT2 inhibitors as cardioprotective and anticancer allies. Hearts 5, 529\u2013546 (2024).","journal-title":"Hearts"},{"key":"49196_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal. Transduct. Target. therapy. 6, 425 (2021).","journal-title":"Signal. Transduct. Target. therapy"},{"key":"49196_CR37","doi-asserted-by":"publisher","first-page":"188716","DOI":"10.1016\/j.bbcan.2022.188716","volume":"1877","author":"M Kciuk","year":"2022","unstructured":"Kciuk, M., Gieleci\u0144ska, A., Mujwar, S., Mojzych, M. & Kontek, R. Cyclin-dependent kinases in DNA damage response. Biochim. et Biophys. Acta (BBA)-Reviews Cancer. 1877, 188716 (2022).","journal-title":"Biochim. et Biophys. Acta (BBA)-Reviews Cancer"},{"key":"49196_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41418-022-01069-x","volume":"30","author":"AP Tran","year":"2023","unstructured":"Tran, A. P. et al. Long-term p21 and p53 dynamics regulate the frequency of mitosis events and cell cycle arrest following radiation damage. Cell. Death Differ. 30, 660\u2013672 (2023).","journal-title":"Cell. Death Differ."},{"key":"49196_CR39","doi-asserted-by":"publisher","first-page":"112455","DOI":"10.1016\/j.biopha.2021.112455","volume":"145","author":"AM Abdelhamid","year":"2022","unstructured":"Abdelhamid, A. M. et al. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomed. Pharmacother. 145, 112455. https:\/\/doi.org\/10.1016\/j.biopha.2021.112455 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"49196_CR40","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.3390\/cancers14235811","volume":"14","author":"M Dutka","year":"2022","unstructured":"Dutka, M. et al. SGLT-2 inhibitors in cancer treatment\u2014mechanisms of action and emerging new perspectives. Cancers 14, 5811 (2022).","journal-title":"Cancers"},{"key":"49196_CR41","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2174\/1871520620666200612144124","volume":"20","author":"D Dayer","year":"2020","unstructured":"Dayer, D., Tabandeh, M. R. & Kazemi, M. The radio-sensitizing effect of pharmacological concentration of ascorbic acid on human pancreatic Cancer cells. Anti-Cancer Agents Med. Chemistry-Anti-Cancer Agents). 20, 1927\u20131932 (2020).","journal-title":"Anti-Cancer Agents Med. Chemistry-Anti-Cancer Agents)"},{"key":"49196_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2144\/btn-2022-0034","volume":"75","author":"R Sule","year":"2023","unstructured":"Sule, R., Rivera, G. & Gomes, A. V. Western blotting (immunoblotting): history, theory, uses, protocol and problems. Biotechniques 75, 99\u2013114 (2023).","journal-title":"Biotechniques"},{"key":"49196_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s42255-022-00591-z","volume":"4","author":"MP Murphy","year":"2022","unstructured":"Murphy, M. P. et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat. metabolism. 4, 651\u2013662 (2022).","journal-title":"Nat. metabolism"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49196-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:21:37Z","timestamp":1781824897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49196"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49196-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This experimental study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Ethical code: IR.AJUMS.REC.1400.460).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19102"}}